[Comparison of capacities of bubble-oxygenators].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Takeda.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The effects of bromhexine, a mucolytic agent, on secretory activities of canine tracheal secretory cells and on behaviour of glycoprotein in these secretory cells were investigated histologically and histochemically. Following bromhexine treatment, the number of total glycoprotein-containing goblet cells (GC) remained the same. The number of acid glycoprotein (AGP)-containing GC was reduced concentration-dependently, while neutral glycoprotein (NGP)-containing GC significantly increased with doses of 10-6, 10-5 and 10-4M. The number of sulphated glycoprotein (SGP) in AGP-containing GC decreased concentration-dependently. Acinar inner diameter of the submucosal gland and an acinar inner diameter of this gland to wall ratio (AIWR) increased with doses of 10-5 and 10-4M. Particularly, AIWR significantly increased with dose of 10-4M. Thickness of the acinus tended to slightly decrease concentration-dependently. AGP content in glandular cells decreased, while NGP content in these cells markedly increased, concentration-dependently. SGP content in the glandular cells decreased. Total saccharide and protein concentrations in the incubation fluid significantly increased with higher concentrations of the treatment, whereas N-acetylhexosamine slightly decreased concentration-dependently. These findings suggest that bromhexine does not enhance secretory activities of GC, but does stimulate the activities of the submucosal glands, when the drug is given in higher concentrations. Bromhexine markedly dissolves AGP in granules of the secretory cells.
Explore the source record for details and available documents.
The effects of bromhexine on secretory activities of canine tracheal secretory cells with stimulated synthesis of acid glycoprotein (AGP) by pilocarpine 10(-6)M treatment an on behaviour of glycoprotein in these secretory cells were investigated histologically and histochemically. Following bromhexine treatment, the number of total glycoprotein-containing goblet cells (GC) remained unchanged. The numbers of AGP-containing and sulphated glycoprotein (SGP)-containing GC significantly decreased, while neutral glycoprotein (NGP)-containing GC significantly increased. The acinar inner diameter of the submucosal gland and the acinar inner diameter of this gland to wall ratio slightly increased. Thickness of the acinus and Reid index slightly decreased, concentration-dependently. AGP and SGP content in glandular cells decreased, while NGP content in these cells markedly increased. Bromhexine 10(-5) and 10(-4)M treatment resulted in increased total saccharide and protein concentrations in the incubation fluid, whereas the agent significantly decreased N-acetylhexosamine, in a concentration-dependent manner. These findings suggest that while bromhexine does not stimulate secretory activities of GC, it does slightly stimulate the activities of the submucosal glands. Bromhexine markedly dissolves AGP in the granules of these secretory cells.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Serum turnover and urinary excretion of digoxin with or without oral furosemide were studied in six healthy subjects who received 0.006 mg/kg body weight digoxin intravenously. During furosemide treatment, the total amount of urinary digoxin did not change but the digoxin clearance during the diuretic phase and the digoxin excretion after the diuresis decreased significantly. The average serum half-life was prolonged from 37 hours in the control period to 86 hours in the furosemide period. Decreased glomerular filtration rate by volume depletion might have been responsible for the decreased excretion of digoxin, but there was no significant difference in urine volume after diuresis between the two periods, suggesting the possibility of inhibition of tubular secretion of digoxin by furosemide. It is also possible that serum digoxin concentration may be elevated if furosemide were given more frequently.